JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB209384

Anti-RIP3 (phospho S227) antibody [EPR9627]

Be the first to review this product! Submit a review

|

(116 Publications)

Anti-RIP3 (phospho S227) antibody [EPR9627] (ab209384) is a rabbit monoclonal antibody detecting RIP3 in Western Blot, ELISA, Dot Blot. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency
- Over 70 publications

View Alternative Names

RIP3, RIPK3, Receptor-interacting serine/threonine-protein kinase 3, RIP-like protein kinase 3, Receptor-interacting protein 3, RIP-3

4 Images
Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)
  • WB

Supplier Data

Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)

Blocking/Dilution buffer : 5% NFDM/TBST.

Image provided by Xiaodong. Wang, National Institute of Biological Sciences, Beijing.

All lanes:

Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (ab209384)

Lane 1:

Untreated HT-29 (Human colorectal adenocarcinoma cell line) whole cell lysate

Lane 2:

HT-29 (Human colorectal adenocarcinoma cell line) treated with 20 ng/ml TNF alpha,100 nM Smac mimetic, and 20 uM z-VAD for 6 h and then harvested whole cell lysate

Predicted band size: 57 kDa

Observed band size: 70 kDa

false

Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)
  • WB

Lab

Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)

Blocking/Diluting buffer and concentration 5% NFDM/TBST

All lanes:

Western blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (ab209384) at 1/1000 dilution

Lane 1:

HT-29 (Human colorectal adenocarcinoma epithelial cell) treated with 20 ng/ml TNF alpha, 100 nM Smac mimetic and 20μM VAD-FMK for 6 h cell lysate at 10 µg

Lane 2:

HT-29 (Human colorectal adenocarcinoma epithelial cell) cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 57 kDa

Observed band size: 70 kDa

false

Exposure time: 100s

ELISA - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)
  • ELISA

Lab

ELISA - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)

Direct ELISA antibody dose-response curve using ab209384. Antigen concentration of 1000 ng/mL and primary antibody concentration of 0-1000 ng/mL. A Alkaline Phosphatase-conjugated AffiniPure -conjugated goat anti-rabbit IgG (1/2500) was used as the secondary antibody.

Dot Blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)
  • Dot

Supplier Data

Dot Blot - Anti-RIP3 (phospho S227) antibody [EPR9627] (AB209384)

Dot blot analysis of RIP3 (phospho S227) phospho peptide (Lane 1) and RIP3 non-phospho peptide (Lane 2) labeled using ab209384 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100,000 dilution.

Blocking and diluting buffer : 5% NFDM/TBST.

Exposure time : 10 seconds.

  • Carrier free

    Anti-RIP3 (phospho S227) antibody [EPR9627] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR9627

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

Dot, WB, ELISA

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>" }, "Synthetic peptide": { "ELISA-species-checked": "notRecommended", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/1000", "Dot-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Synthetic peptide - Human": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "Dot-species-checked": "notRecommended", "Dot-species-dilution-info": "", "Dot-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Product details

What is this antibody validated in?
Anti-RIP3 (phospho S227) antibody [EPR9627] (ab209384) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), ELISA, Dot Blot in Human samples.

What is the molecular weight of RIP3?
Anti-RIP3 (phospho S227) [EPR9627] (ab209384) specifically detects a band for RIP3 (UniProt: Q9Y572) at a molecular weight of 57kDa.

Trusted by the scientific community
Anti-RIP3 (phospho S227) [EPR9627] (ab209384) was first used in a scientific publication in 2015 and has been cited over 70 times in peer-reviewed journals.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.

Other related products
We have a range of other formats of antibody clone [EPR9627] also available for your convenience: ab209384, Carrier free - ab240383

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

'Receptor-interacting protein kinase 3' (RIP3) also known as RIPK3 is a serine/threonine-protein kinase with a molecular weight of approximately 57 kDa. Mechanically it contains a kinase domain that allows it to phosphorylate specific substrates which is important for mediating its function within the cell. RIP3 is expressed in various tissues with notable presence in the spleen heart and adipose tissue. The protein localizes predominantly in the cytoplasm where it interacts with other cellular proteins to initiate downstream signaling events.
Biological function summary

RIP3 facilitates the execution of necroptosis a form of programmed cell death distinct from apoptosis. It becomes activated upon binding with RIP1 forming a necrosome complex that is essential for this pathway. This complex promotes phosphorylation events that subsequently lead to membrane rupture and cell death. Apart from its role in necroptosis RIP3 also engages in metabolic regulation processes linking energy status and cell death under conditions of stress.

Pathways

RIP3 is a principal component of the necroptotic pathway interacting closely with RIP1 to trigger cell death in conditions where caspase activation is inhibited. Alternatively it integrates into metabolic pathways participating in sensing and responding to changes in cellular energy states. The interplay between RIP3 and RIP1 within these pathways illustrates their shared involvement in maintaining cellular homeostasis and triggering cell death when necessary.

RIP3 has significant implications for conditions involving excessive or dysfunctional cell death such as inflammatory diseases and reperfusion injury. The necroptotic activity of RIP3 can exacerbate inflammation by promoting the release of pro-inflammatory factors upon cell death. Furthermore during ischemia-reperfusion injury increased RIP3 activity in conjunction with MLKL another necroptosis-associated protein contributes to tissue damage highlighting its potential as a therapeutic target for reducing cell death-related tissue damage.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Serine/threonine-protein kinase that activates necroptosis and apoptosis, two parallel forms of cell death (PubMed : 19524512, PubMed : 19524513, PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 29883609, PubMed : 32657447). Necroptosis, a programmed cell death process in response to death-inducing TNF family members, is triggered by RIPK3 following activation by ZBP1 (PubMed : 19524512, PubMed : 19524513, PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 29883609, PubMed : 32298652). Activated RIPK3 forms a necrosis-inducing complex and mediates phosphorylation of MLKL, promoting MLKL localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage (PubMed : 19524512, PubMed : 19524513, PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 25316792, PubMed : 29883609). In addition to TNF-induced necroptosis, necroptosis can also take place in the nucleus in response to orthomyxoviruses infection : following ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear RIPK3 catalyzes phosphorylation and activation of MLKL, promoting disruption of the nuclear envelope and leakage of cellular DNA into the cytosol (By similarity). Also regulates apoptosis : apoptosis depends on RIPK1, FADD and CASP8, and is independent of MLKL and RIPK3 kinase activity (By similarity). Phosphorylates RIPK1 : RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (PubMed : 19524513). In some cell types, also able to restrict viral replication by promoting cell death-independent responses (By similarity). In response to Zika virus infection in neurons, promotes a cell death-independent pathway that restricts viral replication : together with ZBP1, promotes a death-independent transcriptional program that modifies the cellular metabolism via up-regulation expression of the enzyme ACOD1/IRG1 and production of the metabolite itaconate (By similarity). Itaconate inhibits the activity of succinate dehydrogenase, generating a metabolic state in neurons that suppresses replication of viral genomes (By similarity). RIPK3 binds to and enhances the activity of three metabolic enzymes : GLUL, GLUD1, and PYGL (PubMed : 19498109). These metabolic enzymes may eventually stimulate the tricarboxylic acid cycle and oxidative phosphorylation, which could result in enhanced ROS production (PubMed : 19498109).. (Microbial infection) In case of herpes simplex virus 1/HHV-1 infection, forms heteromeric amyloid structures with HHV-1 protein RIR1/ICP6 which may inhibit RIPK3-mediated necroptosis, thereby preventing host cell death pathway and allowing viral evasion.
See full target information RIPK3 phospho S227

Publications (116)

Recent publications for all applications. Explore the full list and refine your search

Cell death discovery 11:413 PubMed40877228

2025

Discovery of Zharp1-163 as a dual inhibitor of ferroptosis and necroptosis for the treatment of inflammatory disorders and kidney injury.

Applications

Unspecified application

Species

Unspecified reactive species

Yuting Ji,Shujing Du,Jingjing Li,Haikuo Ma,Xinhui Wang,Yongjin Hao,Zhanhui Li,Haohao Lu,Hao Liu,Chengkui Yang,Xiaohu Zhang,Sudan He

Research (Washington, D.C.) 8:0823 PubMed40822127

2025

USP53 Drives Ethanol-Induced Myocardial Injury by Promoting K63 Deubiquitination-Dependent RIPK1 Activation at K377.

Applications

Unspecified application

Species

Unspecified reactive species

Jichen Pan,Xiaolin Liu,Xiao Li,Shanshan Wang,Yuliang Zhao,Chong Yuan,Dongdong Liu,Liyan Wang,Meng Zhang,Fengming Liu,Mei Zhang,Shen Dai

Bioactive materials 53:737-753 PubMed40801020

2025

Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Rui Cai,Meng Wang,Mengting Pan,Zhiwu Zhang,Qiang Jia,Longbao Feng,Zhongjian Yu,Lu Liu,Tongyu Zhu,Silin Cai,Han Tian,Jiangyu Zhang,Rui Guo,Yanfang Zheng

Nature communications 16:7360 PubMed40783390

2025

Opposing regulation of the K63-linked polyubiquitination of RIPK3 by SMURF1 and USP5 in necroptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Chi Hyun Hwang,Minhong Lee,Ju Won Kim,Young Woo Nam,Gyuho Hwang,Hyun Sung Ryu,Jinho Seo,Eun-Woo Lee,Hyuk Wan Ko,Jaewhan Song

Nature communications 16:7309 PubMed40774959

2025

RIPK1 kinase drove brain microvascular endothelial cells death and blood-brain barrier disruption in neonatal Escherichia coli meningitis.

Applications

Unspecified application

Species

Unspecified reactive species

Xuhang Wang,Yuhan Zhang,Xinru Chen,Kailai Fu,Jiaqi Cui,Jiaoling Wu,Yu Sun,Jianluan Ren,Feng Xue,Jianjun Dai,Fang Tang

Cell death discovery 11:345 PubMed40715038

2025

RIPK1 S213E mutant suppresses RIPK1-dependent cell death by preventing interactions with RIPK3 and CASP8.

Applications

Unspecified application

Species

Unspecified reactive species

Ning Nan,Hong Hu,Xinxin Zhu,Jia Liu,Feiyang Yuan,Zhijie Li,Huayi Wang

Cell death & disease 16:426 PubMed40456737

2025

FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death.

Applications

Unspecified application

Species

Unspecified reactive species

Byeong-Ju Kim,Sun Mi Hong,Hyun-Jin Noh,Jihye Kim,Su-Yeon Seon,Jeong-Eun Lee,Da-Hye Jeong,Ju-Mi Park,Sejeong Park,Sanghoon Lee,Jaewoo Kang,Dakeun Lee,Michael J Morgan,You-Sun Kim

Frontiers in pharmacology 16:1586705 PubMed40458801

2025

Gambogic acid targets HSP90 to alleviate DSS-induced colitis via inhibiting the necroptosis of intestinal epithelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

Yuanyuan Wang,Siqi Liu,Keyi Lu,Erping Xu,Zhibin Wang

Pathogens (Basel, Switzerland) 14: PubMed40430799

2025

Modulates RIPK3 Cellular Levels but Does Not Inhibit Necroptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Thomas E Siff,Paige E Allen,David L Armistead,Jason R Hunt,Steven J Rolland,Hervé Agaisse,Jason A Carlyon

International journal of molecular sciences 26: PubMed40332549

2025

Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma.

Applications

Unspecified application

Species

Unspecified reactive species

Aditya Sharma,Daniel Pettee,Christine Mella,Catherine Hord,Maximilian Brockwell,Samantha Hardy,Hope C Ball,Fayez F Safadi,Steven J Kuerbitz
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com